Giuseppina Raspaglio

Author PubWeight™ 11.93^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.	Clin Cancer Res	2005	2.21
2	The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.	Cancer Res	2005	1.20
3	Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.	Mol Pharmacol	2003	1.20
4	MiR-200c and HuR in ovarian cancer.	BMC Cancer	2013	1.18
5	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77.	Cancer Res	2009	1.13
6	Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?	Curr Cancer Drug Targets	2007	0.99
7	Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma.	Biochem Pharmacol	2009	0.95
8	Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine.	Mol Cancer Ther	2006	0.83
9	Gli family transcription factors are drivers of patupilone resistance in ovarian cancer.	Biochem Pharmacol	2012	0.81
10	From plasma membrane to cytoskeleton: a novel function for semaphorin 6A.	Mol Cancer Ther	2008	0.79
11	RON and cisplatin resistance in ovarian cancer cell lines.	Oncol Res	2010	0.79